A proof‐of‐principle study comparing barrier function and cell morphology in face and body skin

OBJECTIVE The purpose of this pilot in vivo study was to investigate corneocyte size and transepidermal water loss (TEWL) in facial cheek and volar forearm skin as a function of consecutive tape stripping. Changes in corneocyte size and transepidermal water loss (TEWL) were measured as a function of stratum corneum (SC) depth at both anatomical sites. To our knowledge, this is the first published quantitative comparison based on these parameters. This work complements our previously published studies on face skin barrier recovery at 24 h and 4 weeks post‐tape stripping [Gorcea et al., Skin Res. Technol., 19, 2013, e375‐e382; Gorcea et al., Int. J. Cosmet. Sci. 35, 2013, 250]. METHODS Transepidermal water loss in vivo measurements of forearm and facial skin sites were taken before tape stripping commenced (baseline) and after each tape was collected. Optical microscopy and image analysis techniques were employed to characterize corneocyte size as a function of skin depth (tape strip number) for both anatomical sites. RESULTS Transepidermal water loss increased significantly from baseline with sequential tape stripping at both anatomical skin sites. Volar forearm skin required approximately three times as many tapes to ‘damage’ the SC barrier (arbitrarily defined as twice baseline TEWL) compared to facial cheek skin demonstrating significant differences in barrier properties between cheeks and forearms (P < 0.05). Corneocyte size decreased significantly with depth for both sites (P < 0.001). Corneocytes from face skin were significantly smaller than corneocytes from volar forearm skin. CONCLUSION Statistically significant differences between facial and body skin stratum corneum cell morphology and transepidermal water loss were demonstrated and quantitatively measured as a function of tape stripping

Parasitic fauna in farmed trouts in Tismana, Romania

Epidemiological study of the general prevalence of parasites in trouts in the two farms from have revealed various aspects depending on the species studied, depending on season, age category (size) but also from a farm to another

ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation:background and design of the ADMIRAL trial

Acute myeloid leukemia (AML) is a heterogeneous disease with cure rates of only 30–40% in patients &lt;60 years old. Cytogenetic and molecular markers have improved our understanding of the different prognostic entities in AML. FLT3 mutations are present in 30–40% of AML cases, conferring a poor prognosis with reduced survival. AXL activates FLT3, impacting adversely on outcome. Both FLT3 and AXL constitute promising molecular targets. ASP2215 (gilteritinib) is a novel, dual FLT3/AXL inhibitor with promising early phase trial data (NCT02014558). A Phase III randomized multicenter clinical trial, comparing ASP2215 to salvage chemotherapy in relapsed/refractory AML with FLT3-mutations is now open to recruitment (NCT02421939). Trial design and objectives are discussed here. </jats:p